The AI-led stock rally that rewarded mega-cap technology stocks has finally started to trickle down to other industry players that were seemingly not related to the AI and tech industry.
Elevatus Welath Management acquired a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 24,650 shares of the company’s stock, valued at approximately $243,000. Other institutional investors also recently bought and sold shares of the […]
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report)’s share price fell 5.5% during trading on Wednesday . The stock traded as low as $8.45 and last traded at $8.50. 1,189,638 shares changed hands during trading, a decline of 81% from the average session volume of 6,164,144 shares. The stock had previously closed at $8.99. Wall […]
Humacyte (NASDAQ:HUMA – Get Free Report) and Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership. Insider and Institutional Ownership 44.7% of Humacyte shares are […]
Recursion Pharmaceuticals, Inc. announced that Robert Hershberg, M.D., Ph.D, has been appointed the new Chair of the Board of the company, effective at the end of this term, as Martin Chavez exits.